Entrada Therapeutics Inc (NASDAQ: TRDA) is 17.30% higher on its value in year-to-date trading and has touched a low of $10.75 and a high of $18.17 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TRDA stock was last observed hovering at around $17.50 in the last trading session, with the day’s gains setting it 0.2%.
Currently trading at $17.70, the stock is 12.46% and 11.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.18 million and changing 1.14% at the moment leaves the stock 20.97% off its SMA200. TRDA registered 9.53% gain for a year compared to 6-month gain of 28.91%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 10.90% loss in the last 1 month and extending the period to 3 months gives it a 14.42%, and is 7.14% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.31% over the week and 5.28% over the month.
Entrada Therapeutics Inc (TRDA) has around 159 employees, a market worth around $658.44M and $239.40M in sales. Current P/E ratio is 5.98. Profit margin for the company is 43.63%. Distance from 52-week low is 64.65% and -2.59% from its 52-week high. The company has generated returns on investments over the last 12 months (21.50%).
The EPS is expected to grow by 326.00% this year.
Entrada Therapeutics Inc (TRDA) Top Institutional Holders
135.0 institutions hold shares in Entrada Therapeutics Inc (TRDA), with institutional investors hold 92.03% of the company’s shares. The shares outstanding are 33.44M, and float is at 21.54M with Short Float at 9.61%. Institutions hold 80.07% of the Float.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 4.87 million shares valued at $69.34 million. The investor’s holdings represent 14.5261% of the TRDA Shares outstanding. As of 2024-06-30, the second largest holder is MPM ASSET MANAGEMENT LLC with 4.43 million shares valued at $$63.07 million to account for 13.2125 of the shares outstanding. The other top investors are 5AM VENTURE MANAGEMENT, LLC which holds 4.41 million shares representing 13.1605% and valued at over $62.82 million, while PRICE T ROWE ASSOCIATES INC /MD/ holds 9.3574 of the shares totaling 3.13 million with a market value of $44.67 million.
Entrada Therapeutics Inc (TRDA) Insider Activity
The most recent transaction is an insider sale by Dowden Nathan J,the company’sPresident & COO. SEC filings show that Dowden Nathan J sold 27,097 shares of the company’s common stock on Aug 16 ’24 at a price of $16.27 per share for a total of $0.44 million. Following the sale, the insider now owns 0.13 million shares.
Still, SEC filings show that on Jul 15 ’24, Sethuraman Natarajan (Chief Scientific Officer) disposed off 638 shares at an average price of $18.00 for $11484.0. The insider now directly holds 188,814 shares of Entrada Therapeutics Inc (TRDA).
